drugset / Trial / NCT04189952
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.
Timeline
- Start
- 2020-09-22
- Primary completion
- 2021-06-30
- Completion
- 2022-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Oral |
| Background | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |
| Background | Ifosfamide | Small molecule | 5 g | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |